Sign inJoin waitlistJoin the waitlist

Ahmed Galal

Hematology · Oncology Hematology Care Inc

Credentials: · · · · · · ·

History

University Of Toronto Hospitals
Until 2002
University Of Western Ontario
Until 2001
Dalhousie University
Until 1999
Dalhousie University
Until 1997
Faculty Of Medicine Menoufia University
Until 1990
Ain Shams University Hospitals
Until 1987
Ain Shams University Faculty Of Medicine
1985

Research

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
The Lancet Oncology · 2011 · 160 citations
Stereochemistry-dependent cytotoxicity of some artemisinin derivatives
Journal of Natural Products · 1997 · 95 citations
Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction
International Journal of Cancer · 2009 · 83 citations

Chenyu Lin
6 papers · 3 as a fellow
Aaron Logan
3 papers
Abdullah Ladha
3 papers
Akash Mukherjee
3 papers
Bhagirathbhai Dholaria
3 papers
BS
Bijal Shah
3 papers
Divya Koura
3 papers
Evan Chen
3 papers
Gregory Roloff
3 papers · 3 as a fellow
Ibrahim Aldoss
3 papers
Ibrahim Muhsen
3 papers · 3 as a fellow
JP
Jae Park
3 papers

Clinical trials

Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas
Principal investigator · Withdrawn · Phase 1
Ahmed Galal, MD
2020–2023
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Site PI · Recruiting · Phase 2
Allotera Therapeutics
2025–2028
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Site PI · Recruiting · Phase 2
Allogene Therapeutics
2024–2032